Medicare program; Medicare prescription drug benefit. Final rule.
about
Challenges to integrating pharmacogenetic testing into medication therapy managementContingent valuation and pharmacists' acceptable levels of compensation for medication therapy management services.Effects of Medicare Part D on guideline-concordant pharmacotherapy for bipolar I disorder among dual beneficiaries.Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteriaMedicare beneficiaries' knowledge of and choices regarding Part D, 2005 to the present.Disparity implications of Medicare eligibility criteria for medication therapy management servicesMedicaid's expenditures for newer pharmacotherapies for adults with disabilitiesExploring successful community pharmacist-physician collaborative working relationships using mixed methods.Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility in non-Medicare population.Effects of medicare part d on disparity implications of medication therapy management eligibility criteria.Utility of a brief screening tool for medication-related problemsAn introductory pharmacy practice experience based on a medication therapy management service model.Predictors of medication-related problems among medicaid patients participating in a pharmacist-provided telephonic medication therapy management program.Pharmacy students' knowledge of the Medicare drug benefit and intention to provide Medicare medication therapy management services.Trends in Medicare Part D Medication Therapy Management Eligibility Criteria.Medicare Part D's effect on the under- and overuse of medications: a systematic review.Association between the Part D coverage gap and adverse health outcomes.Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups.Racial and ethnic disparities in meeting Part D MTM eligibility criteria among the non-Medicare populationHistorical trend of disparity implications of Medicare MTM eligibility criteria.Disparity implications of the Medicare medication therapy management eligibility criteria: a literature review.Problem-based learning using the online Medicare Part D Plan Finder tool.What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings.The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefitsPotential health implications of racial and ethnic disparities in meeting MTM eligibility criteria.Receipt of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers among Medicare Beneficiaries with Diabetes and HypertensionSubsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.Racial and ethnic disparities in meeting MTM eligibility criteria among patients with asthma.Fellowships in community pharmacy research: Experiences of five schools and colleges of pharmacy.Disparity Implications of Proposed 2015 Medicare Eligibility Criteria for Medication Therapy Management Services.Medication therapy management services provided by student pharmacists.Characterization of actions taken during the delivery of medication therapy management: A time-and-motion approach.Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study
P2860
Q28082835-B0A421BC-8895-4D70-8A29-8B2BD7233213Q30384936-E0853A74-CFAC-4A91-8FBB-30AB420EA8DFQ33687751-C238733D-47AF-40DA-B0BE-11770EBF5D5DQ33865820-1777467B-EFE5-4E58-BEC9-A27648CFF954Q33910030-A4D772BC-5C7E-4484-9321-6FCFD513C9D4Q34017549-90D43366-6043-472C-90DB-CA048E69D8BDQ34022273-60DDD49F-F76B-4735-85D6-CB4E23B043EDQ34328776-EB1EE913-4905-466F-9601-3C57492D35DDQ34417646-5C80C475-51B8-4CEC-998B-C9C632952F7CQ34662775-08ED05FF-464A-4913-8796-1324F4F1C382Q34792508-D0E611B8-C2F1-4267-9B47-D62F18D4019CQ35085815-EF1D8530-4017-44CC-BD0F-52DBCB6E85E7Q35126151-D26B1327-708C-45E9-9452-3C8F34BE77F9Q35589861-BBB56A3B-45D9-41D4-808C-CC762C0A678DQ35879167-B2F093BA-FC2C-45A5-B99C-8ED4B1720E6EQ36051887-C9AA2432-035C-43DC-B754-D73A8199D0C7Q36105740-BC6A9F73-14D9-4B8E-9AAD-0E5BE7BF699DQ36164651-6B6C6367-2D33-44B3-8F8B-2E739133E19EQ36243328-3A97872E-93A3-45E8-9D09-A507C3CB72D6Q36503822-6C09F56D-1566-41A3-8FAF-F887AAE654A6Q36546254-77F3AE02-DB0C-488D-BE14-C8ADBC04CCB3Q36756883-E6DA0A39-D753-492F-A72E-51DA4ACE23C7Q36829534-12D582D2-0363-48E9-935A-27AD459FEDD3Q36841041-597B9B66-2580-4E2F-AC58-B8BDB105AFE2Q37196554-7813203F-ABD4-444A-83E5-4315B0EC25C4Q37381150-EA1AA3DE-3CB4-488E-BAE9-3D4C7882312BQ37591388-39AD4423-56B5-42B4-A48A-16CA168DE348Q38765324-30381C62-2BD2-4D67-8D8E-4C90A67D3084Q38817223-61520272-B170-40E5-A471-11EC9DEC5CBCQ38880603-1D84F412-E2C0-45C2-901F-9ED3FD39B3D4Q39063133-B006AFDE-CCB0-4201-8277-970D3C32C00AQ42054304-D2C0F05F-6327-4913-9F43-6AF257DF293AQ47565344-4DAC330A-CC7F-43CB-80F3-6DDA01A575FEQ47641764-3163512D-036E-4DE0-87B0-C1D236CFF4A8Q58768878-7960C799-AFB3-43F4-BC45-E1CF66F14718
P2860
Medicare program; Medicare prescription drug benefit. Final rule.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Medicare program; Medicare prescription drug benefit. Final rule.
@ast
Medicare program; Medicare prescription drug benefit. Final rule.
@en
type
label
Medicare program; Medicare prescription drug benefit. Final rule.
@ast
Medicare program; Medicare prescription drug benefit. Final rule.
@en
prefLabel
Medicare program; Medicare prescription drug benefit. Final rule.
@ast
Medicare program; Medicare prescription drug benefit. Final rule.
@en
P1433
P1476
Medicare program; Medicare prescription drug benefit. Final rule
@en
P2093
Centers for Medicare & Medicaid Services (CMS), HHS
P304
P577
2005-01-01T00:00:00Z